Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) generates a wide range of news relevant to investors, health care professionals and industry observers. As a global, diversified pharmaceutical company with operations in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, its disclosures cover both business performance and strategic activity.
News updates commonly include financial results and segment performance, such as quarterly revenue trends across Salix, International, Solta Medical, Diversified Products and Bausch + Lomb. The company also releases information on capital structure actions, including exchange offers for senior secured notes and amendments to credit agreements at Bausch Health and Bausch + Lomb, which are detailed in press releases and Form 8-K filings.
Bausch Health’s news flow highlights business development and acquisitions, for example the acquisition of DURECT Corporation to expand its hepatology portfolio and the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd. to strengthen Solta Medical’s distribution in China. Product and geographic expansion updates, such as OraPharma’s commercial expansion into Canada and Puerto Rico and regulatory milestones for aesthetic devices, also feature prominently.
In addition, the company announces conference participation and investor events, including presentations at healthcare conferences where management provides strategic and business updates and may discuss guidance ranges. For those tracking BHC, this news page offers a centralized view of official announcements on operations, financing, governance and growth initiatives. Investors and followers of the pharmaceutical and medical aesthetics sectors can review these items to understand how Bausch Health is executing on its stated priorities and managing its diversified portfolio.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced its subsidiary, Solta Medical Corporation, has filed a registration statement for a proposed IPO of its common shares. The share price and offering size are yet to be determined. Solta aims to list on the Nasdaq under the symbol 'SLTA'. Bausch Health has completed internal steps for launching both Solta and Bausch + Lomb IPOs, pending regulatory approvals. Major investment firms, including Goldman Sachs and Morgan Stanley, are managing the offering.
Bausch Health Companies (NYSE/TSX: BHC) will announce its financial results for Q4 and full-year 2021 on February 23, 2022. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Investors can access the call through the company’s Investor Relations website. Bausch Health focuses on improving lives through its health care products, primarily in eye health, gastroenterology, and dermatology.
Bausch + Lomb partners with Prevent Blindness for the seventh year during AMD Awareness Month, launching a campaign aimed at educating the public on Age-Related Macular Degeneration (AMD), which affects 16 million adults in the U.S. The initiative aims to raise awareness and funds, contributing $1 for each social media interaction, with a goal of $50,000. Bausch + Lomb's president emphasized the importance of eye examinations, as early diagnosis is crucial. The company also plans to release its Visionary Report to identify AMD education gaps.
Bausch Health Companies (BHC) has priced an offering of $1.0 billion in 6.125% senior secured notes due 2027. The proceeds will be utilized for refinancing efforts, encompassing existing loans and the redemption of senior notes due 2025. The refinancing will involve $2.5 billion in term loans and a $975 million revolving credit facility, contingent on the completion of the Bausch + Lomb IPO. The Notes are secured by existing assets and are offered under specific exemptions from registration laws.
Bausch Health Companies Inc. (NYSE/TSX: BHC) has launched a $1.0 billion offering of new senior secured notes due 2027. The company also plans to refinance its existing credit agreement, which includes approximately $2.5 billion in new term B loans and a $975 million revolving credit facility. Proceeds will fund the redemption of outstanding 6.125% and 9.000% senior notes due 2025 and related expenses. The redemption is conditional upon completing the refinancing and receiving at least $7.0 billion from related transactions. The offering is not registered under U.S. securities laws.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that Dr. Yehia Hashad will join Bausch + Lomb as executive vice president of Research & Development (R&D) and chief medical officer (CMO) effective January 31, 2022. Dr. Hashad brings over 25 years of experience in the pharmaceutical industry, with significant expertise in ophthalmic pharmaceuticals from Allergan/AbbVie and Novartis. His appointment aims to enhance the R&D capabilities at Bausch + Lomb, a leader in eye health products and services, as the company continues to innovate and build on its 170-year legacy.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to refinance its existing credit agreement, involving $2.5 billion in Term B loans and a $975 million revolving credit facility. The refinancing is contingent upon the initial public offering (IPO) of Bausch + Lomb, expected to enable Bausch Health to designate Bausch + Lomb as an unrestricted subsidiary. Additionally, the company plans to issue $1 billion in secured debt securities to facilitate the redemption of existing notes. The transactions are subject to market conditions and are expected to close in Q1 2022.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced a significant step towards separating its eye health business by filing a Registration Statement on Form S-1 for a proposed IPO of its subsidiary, Bausch + Lomb. The IPO aims to sell common shares in both the U.S. and Canada, with specifics on share quantity and pricing yet to be determined. Major financial institutions like Morgan Stanley and Goldman Sachs are leading the offering, with market conditions influencing the timing and structure of the transaction. There are no assurances regarding the IPO's completion.
Bausch Health Companies (NYSE/TSX: BHC) will present a business and strategic update during a fireside chat at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022. CEO Joseph C. Papa expressed enthusiasm regarding the progress in unlocking company value, highlighting that preparations for the IPOs of Bausch + Lomb and Solta are nearly complete, pending market and regulatory conditions. The presentation will be available on their Investor Relations page.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced that CEO Joseph C. Papa will speak at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 a.m. ET. A live webcast of the event will be available on the company's Investor Relations page. Bausch Health is committed to improving lives through a range of healthcare products, focusing on eye health, gastroenterology, and dermatology.